According to Zhi Tong Finance App, on October 8, the IPO review status of Sakesaisi Biotechnology Co., Ltd. (referred to as: Sakesaisi) on the Shanghai Stock Exchange STAR Market was changed to "terminated." Because Sakesaisi and its sponsor withdrew the issuance and listing application, in accordance with the relevant provisions of Article 63 of the Shanghai Stock Exchange Stock Issuance and Listing Review Rules, the Shanghai Stock Exchange terminated its issuance and listing review.
The prospectus shows that Sakesaisi focuses on the research and development, production, and sales of absorbable implantable and interventional medical devices. After more than twenty years of deep cultivation, the company has systematically built five leading core technology platforms, including PEG functional modification, bio-based polymer material modification, synthetic medical polymer material preparation, extracellular matrix material preparation, and self-assembling peptide material design and preparation. It has become one of the few medical device companies in China capable of simultaneously deploying and maturely operating multiple absorbable medical material platforms, forming a platform-based research and development architecture driven by "material innovation driving product innovation."
Relying on the above platforms, the company has formed a product system of absorbable innovative medical devices covering multiple departments such as neurosurgery, cardiovascular surgery, general surgery, orthopedics, and tumor radiotherapy. The company's absorbable vascular sealing medical glue is the only domestic product in this segment. Since its launch, with stable product performance and good clinical feedback, its market recognition has continued to increase. At present, the company's absorbable vascular sealing medical glue occupies about 70% of the market share in the domestic vascular sealing glue field, successfully achieving import substitution. Currently, the market penetration rate of vascular sealing glue in China is about 10%. With the deepening of market promotion and continuous verification of clinical application effects, this product is expected to further increase its market penetration rate and promote the development and growth of independent brands in China's vascular sealing material field.
The company's composite microporous polyglucosan hemostatic powder has been clinically used in China for more than 10 years. This product maintains a high level in hemostatic effect, safety, and applicability, forming strong brand influence and clinical recognition, and its market share in the segment has long ranked among the top. At present, the company's composite microporous polyglucosan hemostatic powder has a domestic market share of 27.67% in micro powder absorbable hemostatic materials, ranking first in the segment with a solid market position. The company's surgical anti-adhesion liquid has been clinically used for more than 15 years. This product performs well in safety, stability, and ease of use, and has high market acceptance. At present, this product has a 20.53% share in the domestic surgical anti-adhesion material market, ranking second in the industry, and is one of the main brands in the surgical anti-adhesion material field.
In terms of finances, for the 2023, 2024, and 2025 fiscal years, the company achieved operating revenue of approximately 379 million yuan, 331 million yuan, and 338 million yuan, respectively; during the same period, the company achieved net profit of approximately 153 million yuan, 161 million yuan, and 168 million yuan, respectively.